Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study

P. Ambery; T. W. Donner; N. Biswas; J. Donaldson; J. Parkin; C. M. Dayan

doi:10.1089/dia.2015.1510

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study

P. Ambery
, T. W. Donner
, N. Biswas
, J. Donaldson
, J. Parkin
, C. M. Dayan

Immunology and Immunotherapy

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English
Pages (from-to)	S82-S83
Journal	Diabetes Technology and Therapeutics
Volume	17
DOIs	https://doi.org/10.1089/dia.2015.1510
Publication status	Published - 1 Feb 2015

ASJC Scopus subject areas

Endocrinology, Diabetes and Metabolism
Endocrinology
Medical Laboratory Technology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2015.1510

Cite this

Ambery, P., Donner, T. W., Biswas, N., Donaldson, J., Parkin, J., & Dayan, C. M. (2015). Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study. Diabetes Technology and Therapeutics, 17, S82-S83. https://doi.org/10.1089/dia.2015.1510

@article{48d9793d0fce4e5a8c65d4b1722165da,

title = "Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study",

author = "P. Ambery and Donner, \{T. W.\} and N. Biswas and J. Donaldson and J. Parkin and Dayan, \{C. M.\}",

year = "2015",

month = feb,

day = "1",

doi = "10.1089/dia.2015.1510",

language = "English",

volume = "17",

pages = "S82--S83",

journal = "Diabetes Technology and Therapeutics",

issn = "1520-9156",

publisher = "Mary Ann Liebert",

}

Ambery, P, Donner, TW, Biswas, N, Donaldson, J, Parkin, J & Dayan, CM 2015, 'Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study', Diabetes Technology and Therapeutics, vol. 17, pp. S82-S83. https://doi.org/10.1089/dia.2015.1510

Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study. / Ambery, P.; Donner, T. W.; Biswas, N. et al.
In: Diabetes Technology and Therapeutics, Vol. 17, 01.02.2015, p. S82-S83.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Efficacy and safety of low-dose otelixizumab anti-CD3 monoclonal antibody in preserving C-peptide secretion in adolescent type 1 diabetes:DEFEND-2, a randomized, placebo-controlled, double-blind, multi-center study

AU - Ambery, P.

AU - Donner, T. W.

AU - Biswas, N.

AU - Donaldson, J.

AU - Parkin, J.

AU - Dayan, C. M.

PY - 2015/2/1

Y1 - 2015/2/1

UR - https://www.scopus.com/pages/publications/84923098514

U2 - 10.1089/dia.2015.1510

DO - 10.1089/dia.2015.1510

M3 - Comment/debate

AN - SCOPUS:84923098514

SN - 1520-9156

VL - 17

SP - S82-S83

JO - Diabetes Technology and Therapeutics

JF - Diabetes Technology and Therapeutics

ER -